All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD56 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD56. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD56 antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of relapsed refractory myeloma.
CAR Construction : N901-CD28-CD3ζ
Fig.1 CD56R-specific CAR T cells kill CD56-expressing targets in vitro. Chromium release assays of CD56R-CAR+ T cells co-cultured 20:1 with the following targets: Neuroblastoma (CHLA-255, IMR-32, SKN-BE, and SK-N-SH) and SCLC (HTB-119) cell lines; NK-cell leukemia (KHYG1) and glioma/astrocytoma (U87) cell lines. Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K., ... & Heymach, J. V. (2018). Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 37(27), 3686-3697. |
CAR Construction : N901-CD28-CD3ζ
Fig.2 Anti- or pro-tumor cytokine expression. Expression anti- or pro-tumor cytokine of CD4+ and CD8+ CD56R-CAR+ T cells was detected by intracellular flow cytometry after culturing CD3+ CD56R-CAR+ T cells in the diffrent conditions. Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K., ... & Heymach, J. V. (2018). Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 37(27), 3686-3697. |
CAR Construction :
Fig.3 The ability of CD56R-CAR+T to control tumor growth in vivo. CD56R-CAR+ T cells inhibit the growth of human CD56+ tumors in the high/low tumor-burden CD56+ neuroblastoma mouse model.. Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K., ... & Heymach, J. V. (2018). Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 37(27), 3686-3697. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD56 scFv h(41BB-CD3ζ) CART, pCDCAR1 (CAR-T-2-M312-BZ). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION